New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fludarabine phosphate 25 mg/ml - concentrate for injection - 25 mg/ml - active: fludarabine phosphate 25 mg/ml excipient: dibasic sodium phosphate dihydrate sodium hydroxide water for injection - fludarabine ebewe is indicated for the treatment of b-cell chronic lymphocytic leukaemia.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - fludarabine phosphate - concentrate for solution for infusion or injection - fludarabine phosphate 25 milligram(s)/millilitre - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmachemie bv - fludarabine phosphate - concentrate for soln for inj - 25 mg/ml - purine analogues

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - busulfan, quantity: 60 mg - injection, concentrated - excipient ingredients: macrogol 400; dimethylacetamide - busulfan accord is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - fludarabine phosphate -

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - bendamustine hydrochloride - concentrate for solution for infusion - bendamustine

Canada - English - Health Canada

accord healthcare inc - fludarabine phosphate - solution - 25mg - fludarabine phosphate 25mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - bendamustine hydrochloride - powder for concentrate for solution for infusion - 100 milligram(s) - nitrogen mustard analogues; bendamustine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - bendamustine hydrochloride - powder for concentrate for solution for infusion - 25 milligram(s) - nitrogen mustard analogues; bendamustine

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.